[PDF][PDF] SNMMI procedure standard/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors
Somatostatin receptor (SSTR) imaging using PET has replaced scintigraphic imaging using
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …
Efficacy and safety of 177Lu-DOTATATE in lung neuroendocrine tumors: a bicenter study
L Zidan, A Iravani, K Oleinikov… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The purpose of this study was to assess the efficacy and safety of 177Lu-DOTATATE in
patients with somatostatin receptor (SSR)–positive lung neuroendocrine tumors (NETs) …
patients with somatostatin receptor (SSR)–positive lung neuroendocrine tumors (NETs) …
[HTML][HTML] Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
L Boeckxstaens, E Pauwels, V Vandecaveye… - Ejnmmi Research, 2023 - Springer
Abstract Background Fluorine-18-labeled SSAs have the potential to become the next-
generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their …
generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their …
[HTML][HTML] Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy
TR Halfdanarson, N Mallak, S Paulson… - Cancers, 2023 - mdpi.com
Simple Summary Radioligand therapy with [177Lu] Lu-DOTA-TATE is a therapeutic option
for adult patients with somatostatin-receptor–positive gastroenteropancreatic …
for adult patients with somatostatin-receptor–positive gastroenteropancreatic …
Somatostatin Receptor–PET/CT/MRI of Head and Neck Neuroendocrine Tumors
JN Rini, G Keir, C Caravella… - American Journal …, 2023 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Due to its high sensitivity, somatostatin receptor–PET may
detect smaller lesions and more extensive disease than contrast-enhanced MR imaging …
detect smaller lesions and more extensive disease than contrast-enhanced MR imaging …
68Ga-DOTATATE PET/CT in the initial diagnosis of patients with clinical, imaging, and/or biochemical suspicion of a neuroendocrine tumor
68Ga-DOTATATE PET/CT in the Initial Diagnosis of Patients Wi... : Clinical Nuclear
Medicine 68Ga-DOTATATE PET/CT in the Initial Diagnosis of Patients With Clinical, Imaging …
Medicine 68Ga-DOTATATE PET/CT in the Initial Diagnosis of Patients With Clinical, Imaging …
Intra-individual qualitative and quantitative comparison of [68Ga]Ga-DOTATATE PET/CT and PET/MRI
G Lens, N Ahmadi Bidakhvidi… - Therapeutic …, 2023 - journals.sagepub.com
Background: Somatostatin receptor (SSTR) positron emission tomography (PET) is a
cornerstone of neuroendocrine tumor (NET) management. Hybrid PET/magnetic resonance …
cornerstone of neuroendocrine tumor (NET) management. Hybrid PET/magnetic resonance …
[HTML][HTML] Real-Life Use of [68Ga] Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of …
N Bonazzi, E Fortunati, L Zanoni, G Argalia, D Calabrò… - Cancers, 2024 - mdpi.com
Simple Summary Neuroendocrine neoplasms'(NENs) rarity and heterogeneity represent a
clinical challenge. Somatostatin receptor (SST) positron emission tomography/computed …
clinical challenge. Somatostatin receptor (SST) positron emission tomography/computed …
Molecular and Anatomic Imaging of Neuroendocrine Tumors
L Szidonya, EA Park, JJ Kwak… - Surgical Oncology …, 2022 - surgonc.theclinics.com
Neuroendocrine neoplasms (NENs) are a diverse group of tumors originating from
neuroendocrine cells present throughout the body. 1 These tumors share common …
neuroendocrine cells present throughout the body. 1 These tumors share common …
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A
ASCO recently published a rapid recommendation systemic therapy update on lutetium-177
(177Lu)-PSMA-617 (vipivotide tetraxetan) for metastatic castration-resistant prostate cancer …
(177Lu)-PSMA-617 (vipivotide tetraxetan) for metastatic castration-resistant prostate cancer …